Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Impetis Biosciences Ltd. currently manages a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action across its entire filing history. This workload is handled by 1 distinct examiner and 1 distinct art unit, indicating a very narrow point of contact within the United States Patent and Trademark Office. For practitioners, this concentration suggests that prosecution strategies are currently tailored to a single set of examination standards.
The busiest examiner identified in the data is OTTON, ALICIA L, who is currently overseeing 1 pending office action. This figure of 1 busiest examiner pending action accounts for the total volume of pending office actions for the company. Such a direct alignment between the total workload and the busiest examiner's docket highlights a lack of examiner diversity in the current pipeline. Future filings may either continue this trend within the same art unit or expand into new areas of the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18431910 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | OTTON, ALICIA L | 1699 | §103 | Non-Final OA | — | Pending | Feb 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImpetis Biosciences Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alicia L Otton has the most, with 1 of Impetis Biosciences Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
